^
    1d
    Comparison of the enzymatic and cellular profiles of clinical JAK inhibitors for the treatment of myelofibrosis. (PubMed, Blood Neoplasia)
    In conclusion, ruxolitinib was the most potent, and selective JAKinib with no relevant effects in JAK2-independent cells. In contrast, fedratinib, pacritinib, and momelotinib inhibited many other kinases and inhibited cell growth by JAK2-unrelated mechanisms at clinically relevant concentrations.
    Journal
    |
    ACVR1 (Activin A Receptor Type 1)
    |
    Jakafi (ruxolitinib) • Vonjo (pacritinib) • Inrebic (fedratinib) • Ojjaara (momelotinib)
    2d
    ODYSSEY: Study of Momelotinib in Combination With Luspatercept in Participants With Transfusion Dependent Myelofibrosis (clinicaltrials.gov)
    P2, N=68, Recruiting, GlaxoSmithKline | Trial completion date: Nov 2026 --> Mar 2028 | Trial primary completion date: Oct 2026 --> Mar 2027
    Trial completion date • Trial primary completion date
    |
    Reblozyl (luspatercept-aamt) • Ojjaara (momelotinib)
    7d
    A Study of Momelotinib in Participants With Low-risk Myelodysplastic Syndrome (clinicaltrials.gov)
    P2, N=59, Recruiting, GlaxoSmithKline | N=45 --> 59
    Enrollment change
    |
    Ojjaara (momelotinib)
    7d
    RNA dicing promotes the expression of an oncogenic JAK1 isoform. (PubMed, Cell Rep)
    This results in a better response to the JAK1 inhibitor momelotinib, highlighting RNA dicing's role in patient stratification. Our findings show that RNA dicing diversifies mRNA products, significantly impacting biological functions.
    Journal
    |
    IFNG (Interferon, gamma) • JAK1 (Janus Kinase 1)
    |
    Ojjaara (momelotinib)
    7d
    Pseudo-senescence induced by palbociclib does not sensitise pleural mesothelioma cells to combinations with senolytics. (PubMed, Cell Death Dis)
    The CDK4/6 inhibitors abemaciclib and palbociclib have demonstrated promising results in patient-derived xenograft models of PM...While some cells showed sensitivity to Bcl-xL inhibitors, neither navitoclax nor the specific Bcl-xL inhibitor A-1331852, nor other BH3 mimetics targeting Bcl-2 (venetoclax) or Mcl-1 (S63845) increased cell death when combined with palbociclib...Therefore, we employed inhibitors of these pathways, such as dasatinib, momelotinib or Torin-1, which did not synergise with palbociclib to kill the cells...The differential effects of palbociclib and cisplatin on permanent growth arrest were verified by sorting PM cells based on size and β-galactosidase activity. Our findings underscore the importance of understanding the nature of therapy-induced senescence when assessing the effectiveness of senolytics in different tumour models.
    Journal
    |
    BCL2 (B-cell CLL/lymphoma 2) • IL6 (Interleukin 6) • BCL2L1 (BCL2-like 1) • CXCL8 (Chemokine (C-X-C motif) ligand 8)
    |
    Venclexta (venetoclax) • cisplatin • Ibrance (palbociclib) • dasatinib • Verzenio (abemaciclib) • navitoclax (ABT 263) • S63845 • A-1331852 • Ojjaara (momelotinib) • Torin1
    26d
    Comparing Momelotinib and Ruxolitinib in People With Untreated Myelofibrosis and Low Blood Cell Counts (clinicaltrials.gov)
    P4, N=268, Not yet recruiting, SWOG Cancer Research Network
    New P4 trial
    |
    Jakafi (ruxolitinib) • Ojjaara (momelotinib)
    26d
    M-HArbOr: Momelotinib in Combination With Hypomethylating Agent for Chronic Phase Myelodysplastic Syndromes/Myeloproliferative Overlap Neoplasms and Chronic Neutrophilic Leukemia (clinicaltrials.gov)
    P1, N=18, Recruiting, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Not yet recruiting --> Recruiting
    Enrollment open
    |
    azacitidine • Ojjaara (momelotinib)
    1m
    A Study of JNJ-88549968 for the Treatment of Calreticulin (CALR)-Mutated Myeloproliferative Neoplasms (clinicaltrials.gov)
    P1, N=220, Recruiting, Janssen Research & Development, LLC | Trial completion date: Dec 2027 --> Apr 2028
    Trial completion date • First-in-human • CALR
    |
    CALR (Calreticulin)
    |
    Jakafi (ruxolitinib) • Ojjaara (momelotinib)
    2ms
    Bomedemstat (IMG-7289) in Combination With Momelotinib in Patients With Myelofibrosis (clinicaltrials.gov)
    P2, N=40, Not yet recruiting, United Lincolnshire Hospitals NHS Trust
    New P2 trial
    |
    Ojjaara (momelotinib) • bomedemstat (MK-3543)
    2ms
    GFM-VEXAS-MMB: Momelotinib in VEXAS syndrome (2024-519779-24-00)
    P1/2, N=57, Recruiting, Groupe Francophone Des Myelodysplasies
    New P1/2 trial
    |
    Ojjaara (momelotinib)
    2ms
    SENTRY-2: A Study of Selinexor Monotherapy in Subjects With JAK Inhibitor-naïve Myelofibrosis and Moderate Thrombocytopenia (clinicaltrials.gov)
    P2, N=58, Recruiting, Karyopharm Therapeutics Inc | N=118 --> 58 | Trial primary completion date: Apr 2026 --> Jun 2027
    Enrollment change • Trial primary completion date
    |
    Jakafi (ruxolitinib) • Xpovio (selinexor) • Vonjo (pacritinib) • Ojjaara (momelotinib)
    2ms
    Momelotinib During and After HCT in Myelofibrosis (clinicaltrials.gov)
    P1, N=28, Recruiting, Massachusetts General Hospital | Not yet recruiting --> Recruiting
    Enrollment open
    |
    IDH1 (Isocitrate dehydrogenase (NADP(+)) 1) • IDH2 (Isocitrate Dehydrogenase (NADP(+)) 2) • ASXL1 (ASXL Transcriptional Regulator 1) • SRSF2 (Serine and arginine rich splicing factor 2) • U2AF1 (U2 Small Nuclear RNA Auxiliary Factor 1) • HLA-B (Major Histocompatibility Complex, Class I, B)
    |
    Ojjaara (momelotinib)